Patents Assigned to Janssen Pharmaceuticals, Inc.
  • 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
    Patent number: 10071095
    Abstract: The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 11, 2018
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma, S.A.
    Inventors: Jose Maria Cid-Nunez, Daniel Oehlrich, Andres Avelino Trabanco-Suarez, Gary John Tresadern, Juan Antonio Vega Ramiro, Gregor James MacDonold
  • Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
    Patent number: 10029984
    Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 24, 2018
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988463
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988461
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Triazoles as NR2B receptor inhibitors
    Patent number: 9981950
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 29, 2018
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
    Patent number: 9944598
    Abstract: The present invention concerns mono- or di-substituted indole derivatives (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 17, 2018
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV
    Publication number: 20180093943
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. those in the scheme below: which intermediates and processes are useful in the preparation of the macrocyclic HVC inhibitor Simeprevir.
    Type: Application
    Filed: March 25, 2016
    Publication date: April 5, 2018
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Paul Michel Depré, Dominic John Ormerod, Andras Horvath, Thomas Shaw Moody, Maude Brossat, Olivier Riant, Nicolas Vriamont, Sébastien Francois Emmanuel Lemaire, Sébastien Nicolas J. Hermant
  • COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION
    Publication number: 20180021361
    Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Applicants: JANSSEN PHARMACEUTICALS, INC., ACHILLION PHARMACEUTICALS, INC.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • Combination Therapy Regimen For Treatment Of Selected HCV Genotypes
    Publication number: 20180021360
    Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Applicants: Janssen Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • Chemical compounds
    Patent number: 9814699
    Abstract: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: November 14, 2017
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Pingyun Chen, Ricky Couch, Maosheng Duan, Beth Adams Norton
  • COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION
    Publication number: 20170319572
    Abstract: A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.
    Type: Application
    Filed: July 25, 2017
    Publication date: November 9, 2017
    Applicants: JANSSEN PHARMACEUTICALS, INC., ACHILLION PHARMACEUTICALS, INC.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • Humanized anti-CD134 (OX40) antibodies and uses thereof
    Patent number: 9790281
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: October 17, 2017
    Assignees: BiocerOX Products, B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS
    Publication number: 20170281629
    Abstract: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.
    Type: Application
    Filed: April 5, 2016
    Publication date: October 5, 2017
    Applicant: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Srihari Gopal, Paulien Gerarda Maria Ravenstijn, Alberto Russu, Mahesh Narain Samtani
  • 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
    Patent number: 9737533
    Abstract: The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 22, 2017
    Assignees: Janssen Pharmaceuticals. Inc., Addex Pharma SA
    Inventors: Jose Maria Cid-Nunez, Daniel Oehlrich, Andres Avelino Trabanco-Suarez, Gary John Tresadern, Juan Antonio Vega Ramiro, Gregor James MacDonald
  • Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV
    Publication number: 20170152253
    Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Dominic John Ormerod, Dominique Paul Michel Depre, Andras Horvath
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9605082
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9518129
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 13, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules
    Patent number: 9518128
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 13, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Anti-CD134 (OX40) antibodies and uses thereof
    Patent number: 9475880
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 25, 2016
    Assignees: Biocerox Products, B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Amorphous Salt of a Macrocyclic Inhibitor of HCV
    Publication number: 20160251345
    Abstract: The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 1, 2016
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Peter Jozef Maria Van Remoortere, Roger Petrus Gerebern Vandecruys, Herman De Kock